References
- Papers of special note have been highlighted as:*of interest**of considerable interest
- Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut. 1999;45(Suppl 2):II1–II5.
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140–1156.
- Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S–50S.
- D’Amato M. Genes and functional GI disorders: from casual to causal relationship. Neurogastroenterol Motil. 2013;25:638–649.
- De Moor MH, Van Den Berg SM, Verweij KJ, et al. Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. JAMA Psychiatry. 2015;72:642–650.
- Koloski NA, Jones M, Weltman M, et al. Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia. Neurogastroenterol Motil. 2015;27:1317–1325.
- Koloski NA, Jones M, Kalantar J, et al. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61:1284–1290.
- **Among people free of a FGID at baseline, higher levels of anxiety predict developing new onset FGIDs 12 years later. Among people who did not have elevated levels of anxiety and depression at baseline, those with a FGID at baseline had significantly higher levels of anxiety and depression at 12 year follow-up, highlighting a disturbed bidirectional communication of the brain-gut axis in FGIDs.
- Aro P, Talley NJ, Johansson SE, et al. Anxiety is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study. Gastroenterology. 2015;148:928–937.
- Dragos D, Tanasescu MD. The effect of stress on the defense systems. J Med Life. 2010;3:10–18.
- **Acute stress increases resistance to an infection while chronic psychological stress impairs the immune system.
- Wouters MM, Van WS, Nguyen A, et al. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut. Forthcoming 2015.
- Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut. 2004;53:1102–1108.
- Bohmelt AH, Nater UM, Franke S, et al. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med. 2005;67:288–294.
- Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. Forthcoming 2015.
- Balemans D, Alpizar YA, Nasser Y, et al. Evidence for histamine-mediated sensitization of TRPV1 signaling in sensory neurons in mice and IBS patients. Abstract in Gastroenterology. 2014;146(5):S-220–S-221.
- Cenac N, Altier C, Motta JP, et al. Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity. Gut. 2010;59:481–488.
- Vanuytsel T, Van WS, Vanheel H, et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63:1293–1299.
- Santos J, Saperas E, Nogueiras C, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998;114:640–648.
- Wilder-Smith CH. The balancing act: endogenous modulation of pain in functional gastrointestinal disorders. Gut. 2011;60:1589–1599.
- Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–1365.
- Morgan V, Pickens D, Gautam S, et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54:601–607.
- Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59:1213–1221.
- *The mast cell stabilizer ketotifen increased the threshold of discomfort in patients with IBS with visceral hypersensitivity and improved IBS symptoms. There was, however, no relation between mast cell number, visceral perception and clinical outcome.
- Van Wanrooij SJ, Wouters MM, Van Oudenhove L, et al. Effect of the H1-receptor antagonist ebastin on visceral perception and clinical symptoms in IBS. Abstract in Gastroenterology. 2013;144(5):S-160.